Management of TKI Therapies in Integrated Delivery Network (IDN) Pharmacies

Perspectives on drivers in treatment decisions in the management of hepatocellular carcinoma/renal cell carcinoma (HCC/RCC)

National – February 28, 2022

Faculty Chair

Bhavesh Shah, RPh, BCOP

Boston Medical Center

More Information

  • Virtual series
  • The group of advisors comprised 16 clinical pharmacists, nurse practitioners, and/or pharmacy managers from 11 states across the US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on current treatment practices and future considerations for treatment of RCC and HCC
  • Insights on the following therapies were obtained
    • Management of TKI therapies in solid tumors
    • Patient management within IDN pharmacies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 16 clinical pharmacists, nurse practitioners, and/or pharmacy managers from 11 states across the US

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.